JP2006519189A - 白内障および緑内障を診断および治療するための、ｓｇｋ遺伝子ファミリーの使用 - Google Patents
白内障および緑内障を診断および治療するための、ｓｇｋ遺伝子ファミリーの使用 Download PDFInfo
- Publication number
- JP2006519189A JP2006519189A JP2006501737A JP2006501737A JP2006519189A JP 2006519189 A JP2006519189 A JP 2006519189A JP 2006501737 A JP2006501737 A JP 2006501737A JP 2006501737 A JP2006501737 A JP 2006501737A JP 2006519189 A JP2006519189 A JP 2006519189A
- Authority
- JP
- Japan
- Prior art keywords
- hsgk1
- hsgk3
- gene
- glaucoma
- cataract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 39
- 208000002177 Cataract Diseases 0.000 title claims abstract description 35
- 101150082971 Sgk1 gene Proteins 0.000 title description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 94
- 239000000126 substance Substances 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 34
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims abstract description 29
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 28
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 28
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 28
- 238000012360 testing method Methods 0.000 claims abstract description 22
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 239000003112 inhibitor Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000012634 fragment Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 claims description 35
- 101150058068 SLC2A1 gene Proteins 0.000 claims description 35
- 108091052347 Glucose transporter family Proteins 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 239000000758 substrate Substances 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 102100035493 E3 ubiquitin-protein ligase NEDD4-like Human genes 0.000 claims description 6
- 101710155393 E3 ubiquitin-protein ligase NEDD4-like Proteins 0.000 claims description 6
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 101710165986 Negative regulator of transcription Proteins 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 claims description 3
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims description 3
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims description 3
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims description 2
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 230000002103 transcriptional effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 18
- 102000042092 Glucose transporter family Human genes 0.000 description 17
- 108091000080 Phosphotransferase Proteins 0.000 description 15
- 102000020233 phosphotransferase Human genes 0.000 description 15
- 239000003862 glucocorticoid Substances 0.000 description 13
- 210000000287 oocyte Anatomy 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 13
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- 108010022404 serum-glucocorticoid regulated kinase Proteins 0.000 description 13
- 239000011734 sodium Substances 0.000 description 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 108091006146 Channels Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108091008611 Protein Kinase B Proteins 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 3
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 102100029839 Myocilin Human genes 0.000 description 3
- 101710196550 Myocilin Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- 229960002478 aldosterone Drugs 0.000 description 3
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000009103 reabsorption Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 101000640022 Electrophorus electricus Sodium channel protein Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101000864831 Homo sapiens Serine/threonine-protein kinase Sgk3 Proteins 0.000 description 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 102100030071 Serine/threonine-protein kinase Sgk3 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- 102100020696 Ubiquitin-conjugating enzyme E2 K Human genes 0.000 description 2
- 241000269368 Xenopus laevis Species 0.000 description 2
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000006377 glucose transport Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000003584 mesangial cell Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 1
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101001010787 Homo sapiens Endoribonuclease Proteins 0.000 description 1
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 description 1
- 101000864806 Homo sapiens Serine/threonine-protein kinase Sgk2 Proteins 0.000 description 1
- 101001117143 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Proteins 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150097297 Nedd4 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 101100365036 Rattus norvegicus Scnn1a gene Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108700021949 Xenopus nedd4l Proteins 0.000 description 1
- 102100024150 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- -1 and as a result Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000029215 cell volume homeostasis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/166—Cataract
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/168—Glaucoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10305212A DE10305212A1 (de) | 2003-02-07 | 2003-02-07 | Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom |
| PCT/EP2004/001048 WO2004069258A2 (de) | 2003-02-07 | 2004-02-05 | Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006519189A true JP2006519189A (ja) | 2006-08-24 |
| JP2006519189A5 JP2006519189A5 (enExample) | 2007-03-08 |
Family
ID=32730900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006501737A Pending JP2006519189A (ja) | 2003-02-07 | 2004-02-05 | 白内障および緑内障を診断および治療するための、ｓｇｋ遺伝子ファミリーの使用 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1663246A2 (enExample) |
| JP (1) | JP2006519189A (enExample) |
| KR (1) | KR20050114214A (enExample) |
| CN (1) | CN1771039A (enExample) |
| AU (1) | AU2004210416A1 (enExample) |
| BR (1) | BRPI0407300A (enExample) |
| CA (1) | CA2514703A1 (enExample) |
| DE (1) | DE10305212A1 (enExample) |
| MX (1) | MXPA05008394A (enExample) |
| PL (1) | PL378399A1 (enExample) |
| RU (1) | RU2005127808A (enExample) |
| WO (1) | WO2004069258A2 (enExample) |
| ZA (1) | ZA200506280B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007527875A (ja) * | 2004-03-11 | 2007-10-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 線維症を抑制するための方法 |
| JP2007529423A (ja) * | 2004-03-11 | 2007-10-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 血清・グルココルチコイド誘導性キナーゼのモジュレータの使用を含む、神経精神疾患を治療するためのグルタミン酸受容体の調節方法 |
| JP2014506460A (ja) * | 2011-01-25 | 2014-03-17 | モネル ケミカル センシズ センター | 甘味を提供若しくは調整するための組成物および方法ならびにそれらのスクリーニング方法 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004059781A1 (de) * | 2004-12-10 | 2006-06-22 | Sanofi-Aventis Deutschland Gmbh | Verwendung der Serum-/Glucocorticoid regulierten Kinase |
| WO2007002670A2 (en) * | 2005-06-28 | 2007-01-04 | Bausch & Lomb Incorporated | Method of lowering intraocular pressure |
| JPWO2007037560A1 (ja) * | 2005-09-30 | 2009-04-16 | リンク・ジェノミクス株式会社 | Ｓｇｋ２遺伝子の治療的又は診断的用途 |
| JP5249774B2 (ja) * | 2005-11-22 | 2013-07-31 | マギル ユニバーシティ | 眼内圧調節初期遺伝子およびその使用 |
| WO2008079980A1 (en) * | 2006-12-22 | 2008-07-03 | Alcon Research, Ltd. | Inhibitors of protein kinase c-delta for the treatment of glaucoma |
| DE102008029072A1 (de) * | 2008-06-10 | 2009-12-17 | Lang, Florian, Prof. Dr.med. | Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen |
| KR102357260B1 (ko) * | 2020-12-10 | 2022-02-08 | 주식회사 레피겐엠디 | 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트 |
| CN119303113A (zh) * | 2024-09-03 | 2025-01-14 | 河北大学附属医院 | Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996006863A1 (en) * | 1994-08-30 | 1996-03-07 | University Of Dundee | Agents for inducing apoptosis and applications of said agents in therapy |
| AU6263996A (en) * | 1995-06-07 | 1996-12-30 | Ligand Pharmaceuticals Incorporated | Method for screening for receptor agonists and antagonists |
| US5925523A (en) * | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| DE19708173A1 (de) * | 1997-02-28 | 1998-09-03 | Dade Behring Marburg Gmbh | Zellvolumenregulierte humane Kinase h-sgk |
| WO1999059559A1 (en) * | 1998-05-15 | 1999-11-25 | Joslin Diabetes Center | Independent regulation of basal and insulin-stimulated glucose transport |
| DE69937159T2 (de) * | 1998-12-14 | 2008-06-26 | University Of Dundee, Dundee | Verfahren zur Aktivierung von SGK durch Phosphorylierung. |
| US6399655B1 (en) * | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
| DE19917990A1 (de) * | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
| WO2001004145A2 (en) * | 1999-07-14 | 2001-01-18 | University Of Lausanne | Glutx polypeptide family and nucleic acids encoding same |
| US6416759B1 (en) * | 1999-09-30 | 2002-07-09 | The Regents Of The University Of California | Antiproliferative Sgk reagents and methods |
| US20030236246A1 (en) * | 2002-04-30 | 2003-12-25 | Brazzell Romulus Kimbro | Method for decreasing capillary permeability in the retina |
| DE10225844A1 (de) * | 2002-06-04 | 2003-12-18 | Lang Florian | sgk und nedd als diagnostische und therapeutische targets |
-
2003
- 2003-02-07 DE DE10305212A patent/DE10305212A1/de not_active Withdrawn
-
2004
- 2004-02-05 AU AU2004210416A patent/AU2004210416A1/en not_active Abandoned
- 2004-02-05 WO PCT/EP2004/001048 patent/WO2004069258A2/de not_active Ceased
- 2004-02-05 PL PL378399A patent/PL378399A1/pl not_active Application Discontinuation
- 2004-02-05 CN CNA2004800070348A patent/CN1771039A/zh active Pending
- 2004-02-05 MX MXPA05008394A patent/MXPA05008394A/es unknown
- 2004-02-05 KR KR1020057014582A patent/KR20050114214A/ko not_active Withdrawn
- 2004-02-05 EP EP04708350A patent/EP1663246A2/de not_active Withdrawn
- 2004-02-05 JP JP2006501737A patent/JP2006519189A/ja active Pending
- 2004-02-05 BR BR0407300-2A patent/BRPI0407300A/pt not_active IP Right Cessation
- 2004-02-05 RU RU2005127808/15A patent/RU2005127808A/ru not_active Application Discontinuation
- 2004-02-05 CA CA002514703A patent/CA2514703A1/en not_active Abandoned
-
2005
- 2005-08-05 ZA ZA200506280A patent/ZA200506280B/en unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007527875A (ja) * | 2004-03-11 | 2007-10-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 線維症を抑制するための方法 |
| JP2007529423A (ja) * | 2004-03-11 | 2007-10-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 血清・グルココルチコイド誘導性キナーゼのモジュレータの使用を含む、神経精神疾患を治療するためのグルタミン酸受容体の調節方法 |
| JP2014506460A (ja) * | 2011-01-25 | 2014-03-17 | モネル ケミカル センシズ センター | 甘味を提供若しくは調整するための組成物および方法ならびにそれらのスクリーニング方法 |
| JP2016136974A (ja) * | 2011-01-25 | 2016-08-04 | モネル ケミカル センシズ センターＭｏｎｅｌｌ Ｃｈｅｍｉｃａｌ Ｓｅｎｓｅｓ Ｃｅｎｔｅｒ | 甘味を提供若しくは調整するための組成物および方法ならびにそれらのスクリーニング方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1771039A (zh) | 2006-05-10 |
| BRPI0407300A (pt) | 2006-02-07 |
| AU2004210416A1 (en) | 2004-08-19 |
| PL378399A1 (pl) | 2006-04-03 |
| RU2005127808A (ru) | 2006-05-27 |
| EP1663246A2 (de) | 2006-06-07 |
| CA2514703A1 (en) | 2004-08-19 |
| DE10305212A1 (de) | 2004-08-19 |
| WO2004069258A2 (de) | 2004-08-19 |
| KR20050114214A (ko) | 2005-12-05 |
| MXPA05008394A (es) | 2005-10-05 |
| WO2004069258A3 (de) | 2005-02-24 |
| ZA200506280B (en) | 2006-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Essential roles of the PI3 kinase/Akt pathway in regulating Nrf2-dependent antioxidant functions in the RPE | |
| US20080146540A1 (en) | Methods of diagnosis and treatment for asthma, allergic rhinitis and other respiratory diseases based on haplotype association | |
| JP4751956B2 (ja) | 糖鎖関連遺伝子、およびその利用 | |
| US20070231828A1 (en) | Methods of predicting behavior of cancers | |
| US20090042906A1 (en) | Methods for treating cancers associated with constitutive egfr signaling | |
| Wang et al. | Increased expression of serum amyloid A in glaucoma and its effect on intraocular pressure | |
| JP2006514021A (ja) | Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法 | |
| WO2005032343A2 (en) | Hedgehog signaling in prostate regeneration neoplasia and metastasis | |
| JP2006519189A (ja) | 白内障および緑内障を診断および治療するための、ｓｇｋ遺伝子ファミリーの使用 | |
| Yi et al. | Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines | |
| US20090029904A1 (en) | Compositions and methods for treatment of insulin-resistance diseases | |
| Chen et al. | Osmotic regulation of angiotensin AT1 receptor subtypes in mouse brain | |
| CN100406570C (zh) | 用作诊断和治疗靶标的Sgk和Nedd | |
| US20140378388A1 (en) | Treatment of uterine leiomyomata | |
| JP7025034B2 (ja) | 膵臓炎、腎損傷および腎臓癌を治療および予防するための組成物および方法 | |
| Nchienzia et al. | Hedgehog interacting protein (Hhip) regulates insulin secretion in mice fed high fat diets | |
| Capaccio et al. | A novel germline mutation in peroxisome proliferator-activated receptor γ gene associated with large intestine polyp formation and dyslipidemia | |
| WO2008016118A1 (en) | Agent targeting dopamine receptor and screening method therefor | |
| KR20050016494A (ko) | 진단 및 치료 표적으로 사용되는 ｓｇｋ 및 ｎｅｄｄ | |
| Kleinberger et al. | Genetics of type 2 diabetes: From candidate genes to genome-wide association analysis | |
| US20030068660A1 (en) | Methods of ameliorating arthritis by modulating JNK signalsome activity | |
| WO2006051951A1 (ja) | Cdk5阻害剤を含む糖尿病治療薬 | |
| Falcenberg | Sutent-Sensitive Kinases as Targets for Anti-Diabetic Therapy Development | |
| FALCENBERG | LEHRSTUHL FÜR SYSTEMBIOLOGIE DER PFLANZEN | |
| Caprio et al. | Genetics, Epigenetics and Genomics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070118 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100216 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110125 |